4 Results for "

Tamoxifen-resistant

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "Tamoxifen-resistant" in MCE Product Catalog:

5
5 Cited Publications
Cat. No.: HY-N0401A
CAS No.: 81944-09-4
(Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6 . (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer .
loading...
    loading...
Cat. No.: HY-110201
CAS No.: 63676-22-2
Purity:  99.91%
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

Estrogen receptor modulator 1 (compound 18) is an orally active and selective estrogen receptor modulator (SERM), with a pIC50 of 0.46. Estrogen receptor modulator 1 induces regression of Tamoxifen-resistant, hormone independent xenograft tumors .
loading...
    loading...
Cat. No.: HY-155197
CAS No.: 2922929-63-1
Research Areas:  

Cancer

ER degrader 7 is an estrogen receptor α (ERα) degrader and a tubulin (tubulin) inhibitor. ER degrader 7 inhibits the cell viability of various cancer cell lines. ER degrader 7 disrupts the microtubule network in breast cancer cells, induces G2/M phase cell cycle arrest, and exhibits concentration-dependent accumulation in Tamoxifen-resistant LCC2 cells. ER degrader 7 suppresses tumor growth in vivo without causing body weight loss. ER degrader 7 can be applied in studies related to breast cancer .
loading...
    loading...
Cat. No.: HY-187096
Research Areas:  

Cancer

ERα/RAD51 degrader 1 is a ERα and RAD51 HyT degrader as well as an apoptosis (Apoptosis) inducer. ERα/RAD51 degrader 1 induces conformational changes in helices 11-12 of ERα, promotes the recruitment of Hsp70, and drives the degradation of ERα and RAD51 via the ubiquitin-proteasome pathway. ERα/RAD51 degrader 1 downregulates the expression of BRCA1/2. ERα/RAD51 degrader 1 acts on tamoxifen (HY-13757A)-sensitive and tamoxifen-resistant breast cancer in both in vitro and in vivo models. ERα/RAD51 degrader 1 is applicable to breast cancer-related research (hydrophobic tag: (HY-B0402)) .
loading...
    loading...